Want to see SE:SPRINT full AI Analyst Report?
Top Page
Sprint Bioscience AB
(SPRINT)
Select Model
Select Model
Rating:73Outperform
Price Target:
kr3.50
▲(136.49% Upside)
Action:Reiterated
Date:08/29/26
The score is driven primarily by strong financial performance (high profitability, strong cash generation, and a debt-free balance sheet) and supportive valuation (low P/E). This is partially offset by weaker technicals (price below key short/intermediate moving averages and negative MACD), which suggests limited near-term momentum despite longer-term support above the 200-day average.
Positive Factors
Strong Profitability
Exceptionally high current gross and net margins indicate strong economics and effective conversion of revenue into profit. If sustained, this profitability can fund development internally and improve resilience as the business advances its drug programs.
Negative Factors
Recent Revenue Decline
The recent top-line decline suggests that revenue generation remains uneven, which is a material risk for a partnering-led biotechnology model. Continued weakness could limit funding available for discovery programs and make future earnings less predictable.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Profitability
Exceptionally high current gross and net margins indicate strong economics and effective conversion of revenue into profit. If sustained, this profitability can fund development internally and improve resilience as the business advances its drug programs.
Read all positive factors
Sprint Bioscience AB (SPRINT) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr337.65M
Dividend YieldN/A
Average Volume (3M)252.99K
Price to Earnings (P/E)4.6
Beta (1Y)1.40
Revenue Growth135.48%
EPS GrowthN/A
CountrySE
Employees30
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.72
Shares Outstanding105,515,540
10 Day Avg. Volume353,747
30 Day Avg. Volume252,987
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.14
Price to Sales (P/S)0.81
P/FCF Ratio1.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr84.80M
Sprint Bioscience AB Business Overview & Revenue Model
Company Description
Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immun...
How the Company Makes Money
Sprint Bioscience makes money primarily through partnering and licensing its drug discovery programs to other pharmaceutical or biotechnology companies. Under such agreements, the company can receive upfront payments, research funding, and milesto...
Sprint Bioscience AB Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
86
Very Positive
Cash Flow
74
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 139.15M | 167.17M | 65.64M | 50.48M | 83.00K | 35.11M |
| Gross Profit | 108.57M | 97.33M | 37.30M | 41.79M | -60.91M | 24.68M |
| EBITDA | 79.02M | 98.40M | -17.32M | 396.00K | -60.00M | -24.49M |
| Net Income | 75.65M | 91.74M | -18.28M | -438.00K | -60.17M | -25.35M |
Balance Sheet | ||||||
| Total Assets | 104.28M | 136.66M | 42.05M | 62.38M | 37.42M | 79.14M |
| Cash, Cash Equivalents and Short-Term Investments | 93.26M | 126.70M | 25.06M | 49.93M | 29.49M | 70.64M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 14.20M | 17.48M | 32.78M | 34.60M | 9.23M | 8.68M |
| Stockholders Equity | 90.08M | 119.18M | 9.27M | 27.77M | 28.19M | 70.45M |
Cash Flow | ||||||
| Free Cash Flow | 68.45M | 83.44M | -24.65M | 20.42M | -59.05M | -42.82M |
| Operating Cash Flow | 68.95M | 83.53M | -23.36M | 22.87M | -59.05M | -40.12M |
| Investing Cash Flow | -464.00K | -54.00K | -1.30M | -2.45M | 0.00 | -2.71M |
| Financing Cash Flow | 117.00K | 18.17M | -225.00K | 24.00K | 17.90M | 86.39M |
Sprint Bioscience AB Technical Analysis
Neutral
1.48
Price Trends
3.63
Negative
3.59
Negative
2.65
Positive
Market Momentum
-0.11
Negative
46.87
Neutral
69.94
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SPRINT, the sentiment is Neutral. The current price of 1.48 is below the 20-day moving average (MA) of 3.29, below the 50-day MA of 3.63, and below the 200-day MA of 2.65, indicating a neutral trend. The MACD of -0.11 indicates Negative momentum. The RSI at 46.87 is Neutral, neither overbought nor oversold. The STOCH value of 69.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:SPRINT.
Sprint Bioscience AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | kr515.40M | 2.63 | 63.09% | ― | ― | ― | |
73 Outperform | kr337.65M | 4.58 | 94.09% | ― | 135.48% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | kr182.19M | -7.52 | -56.09% | ― | ― | 14.10% | |
48 Neutral | kr444.04M | -3.99 | -18.05% | ― | ― | 15.97% | |
46 Neutral | kr361.26M | -4.09 | -34.25% | ― | -0.71% | 54.16% | |
43 Neutral | kr1.50B | -3.05 | -99.58% | ― | -87.22% | -70.29% |
* Healthcare Sector Average
SE:SPRINT
Sprint Bioscience AB
3.30
2.70
450.00%
SE:BINV
BioInvent International AB
23.05
-6.80
-22.78%
SE:ELIC
Elicera Therapeutics AB
2.66
-4.25
-61.49%
SE:IVACC
Intervacc AB
1.08
-0.10
-8.60%
SE:IMMU
Immunicum AB
7.14
0.10
1.42%
SE:CANTA
Cantargia AB
1.79
-0.76
-29.80%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.